Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05403801 · ClinicalTrials.gov registry record · NA

STAMP+CBT mHealth for Cancer Pain

A NA study of Advanced Cancer and Palliative Care, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
NA
Development phase
10
Enrollment target
3
Study locations

NCT05403801 is a NA study of Advanced Cancer and Palliative Care that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 10 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05403801, a NA study of Advanced Cancer and Palliative Care, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
NA
Development phase
10 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to test whether a mobile application developed to help people with cancer pain is useful and helpful to patients with cancer.

Interventions

  • BEHAVIORAL STAMP+CBT application

Study Locations (3)

Massachusetts

  • Dana Farber Cancer Institute - Boston
  • Dana-Farber at Merrimack Valley - Methuen

New Hampshire

  • Dana-Farber at Londonderry - Londonderry

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2022-07-01
Est. Completion 2023-06-27
Phase NA

Sponsor

Dana-Farber Cancer Institute

781 total trials

What the Registry Record Tells You About NCT05403801

The ClinicalTrials.gov registry entry for NCT05403801 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which STAMP+CBT application is the first listed.

NCT05403801 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, New Hampshire.

Frequently Asked Questions

What is clinical trial NCT05403801 about?

NCT05403801 is a clinical study titled "STAMP+CBT mHealth for Cancer Pain". The purpose of this study is to test whether a mobile application developed to help people with cancer pain is useful and helpful to patients with cancer.

What is the current status of trial NCT05403801?

This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2022-07-01. Estimated completion is 2023-06-27.

What conditions does trial NCT05403801 study?

This clinical trial studies the following conditions: Advanced Cancer, Palliative Care, Active Cancer, Active Cancer Treatment, Chronic Pain Due to Cancer.

What interventions are being tested in trial NCT05403801?

The interventions under investigation include: STAMP+CBT application (BEHAVIORAL).

Who is sponsoring clinical trial NCT05403801?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05403801 being conducted?

This trial has 3 study locations across Massachusetts, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Advanced Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.